The Medical Letter on Drugs and Therapeutics
Zolpidem Oral Spray (Zolpimist) for Insomnia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Zolpidem oral spray (Zolpimist – NovaDel/ECR), a new formulation of the oral hypnotic zolpidem tartrate (Ambien, and others), has been approved by the FDA for short-term treatment of insomnia characterized by difficulty falling asleep.

ZOLPIDEM — Zolpidem is the most frequently prescribed hypnotic in the US. Rapid-acting with a short half-life, it is available as an immediate-release (IR) tablet, a sublingual tablet (Edluar)1 and an extended-release (ER) tablet (Ambien CR). A new sublingual tablet recently approved for middle-of-the-night awakening (Intermezzo) will be reviewed in a future issue of The Medical Letter.

RELATED DRUGS — Zolpidem, zaleplon (Sonata, and others), and eszopiclone (Lunesta) are benzodiazepine receptor agonists; they are not benzodiazepines, but appear to bind ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Zolpidem Oral Spray (Zolpimist) for Insomnia
Article code: 1384b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian